Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Recurrent Ovarian Cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    285 result(s) found for: Recurrent Ovarian Cancer. Displaying page 3 of 15.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2008-000879-26 Sponsor Protocol Number: 311602-Amendment 1 Start Date*: 2008-08-07
    Sponsor Name:Bayer Schering Pharma AG
    Full Title: (REASON) double-blind, Randomized phase II study to Evaluate the safety and efficacy of Acetyl-l-carnitine in the prevention of SagOpilone-induced peripheral Neuropathy.
    Medical condition: - Advanced refractory or relapsed ovarian cancer - Patients with metastatic hormone-refractory prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10066697 Ovarian cancer recurrent LLT
    9.1 10036909 Prostate cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) NL (Completed) BE (Completed) GB (Completed) DE (Completed) ES (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-015082-31 Sponsor Protocol Number: M10-757 Start Date*: 2010-04-07
    Sponsor Name:Abbott GmbH & Co. KG
    Full Title: A Phase 2 Randomized Clinical Trial of ABT-888 in Combination with Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Subjects with Recurrent High Grade Serous Ovarian Cancer
    Medical condition: Recurrent high grade serous ovarian cancer.
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-005221-12 Sponsor Protocol Number: OCTOPUS-2014 Start Date*: 2015-09-07
    Sponsor Name:NHS Greater Glasgow and Clyde [...]
    1. NHS Greater Glasgow and Clyde
    2. The University of Glasgow
    Full Title: OCTOPUS: Ovarian Cancer Trials of Weekly Paclitaxel - Umbrella Study A Randomised, Phase II Umbrella Trial of a Weekly Paclitxel +/- Novel Agents in Platinum-Resistant Ovarian Cancer
    Medical condition: Ovarian Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057529 Ovarian cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2017-003792-63 Sponsor Protocol Number: UCL/17/0629 Start Date*: 2018-10-23
    Sponsor Name:University College London
    Full Title: Phase II trial of maintenance pembrolizumab following weekly paclitaxel for recurrent ovarian, fallopian tube or peritoneal cancer
    Medical condition: recurrent ovarian/fallopian tube or primary non-mucinous peritoneal cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016180 Fallopian tube cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2009-017171-13 Sponsor Protocol Number: UCL/09/0105 Start Date*: 2010-08-23
    Sponsor Name:University College London
    Full Title: A randomised placebo-controlled trial of saracatinib (AZD0530) plus weekly paclitaxel in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer.
    Medical condition: Platinum-resistant ovarian, fallopian tube or primary peritoneal cancer. The relevant MedDRA codes for recurrent ovarian cancer and fallopian tube cancer are given below.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016180 Fallopian tube cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-000245-41 Sponsor Protocol Number: MITO35b Start Date*: 2021-07-14
    Sponsor Name:ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE
    Full Title: Olaparib beyond progression compared to platinum chemotherapy after secondary cytoreductive surgery in recurrent ovarian cancer patients. The phase III randomized, open label MITO 35b study: a proj...
    Medical condition: Recurrent ovarian cancer patients
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-005027-37 Sponsor Protocol Number: MK3475-B96/ENGOT-ov65 Start Date*: 2022-01-07
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Paclitaxel With or Without Bevacizumab for the Treatment of Platinum-resistant Recurrent Ovarian Cancer...
    Medical condition: Platinum-resistant Recurrent Ovarian Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NO (Trial now transitioned) FI (Trial now transitioned) IT (Trial now transitioned) DK (Trial now transitioned) PL (Trial now transitioned) NL (Trial now transitioned) BE (Trial now transitioned) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-003884-23 Sponsor Protocol Number: VB-111-701/GOG-3018 Start Date*: 2020-06-25
    Sponsor Name:Vascular Biogenics Ltd.
    Full Title: The OVAL Study: A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined with Paclitaxel vs. Paclitaxel Combined with Placebo for the Trea...
    Medical condition: Recurrent Platinum-Resistant Ovarian Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Prematurely Ended) PL (Prematurely Ended) BG (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-005975-17 Sponsor Protocol Number: MO28113 Start Date*: 2012-08-17
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A two-part, randomized Phase II, double-blind, multicenter trial assessing the efficacy and safety of pertuzumab in combination with standard chemotherapy vs. placebo plus standard chemotherapy in ...
    Medical condition: Women with recurrent platinum-resistant or refractory epithelial ovarian cancer and low HER3 mRNA expression.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed) DE (Completed) IT (Completed) NL (Completed) SE (Completed) BE (Completed) AT (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2007-006717-17 Sponsor Protocol Number: CP12-0711 Start Date*: 2008-12-01
    Sponsor Name:ImClone LLC
    Full Title: A Phase 2, Non-randomized, Open-label, Multicenter Study of IMC-1121B in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
    Medical condition: Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-004585-15 Sponsor Protocol Number: Cat-Ovar_2011 Start Date*: 2012-11-29
    Sponsor Name:Charité - Universitätsmedizin Berlin
    Full Title: Single –arm, multicenter phase-II trial for catumaxomab and chemotherapy in patients with recurrent ovarian cancer to investigate the feasibility and clinical activity of initial intraperitoneal ca...
    Medical condition: This is an international, explorative, open-label, prospective, non-randomized multicenter phase II study to assess the feasibility and clinical activity of initial intraperitoneal catumaxomab foll...
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adults Gender: Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-001576-12 Sponsor Protocol Number: SGI-110-02 Start Date*: 2013-07-22
    Sponsor Name:Astex Pharmaceuticals Inc
    Full Title: A Randomized, Controlled, Open-Label, Phase 2 Trial of SGI-110 and Carboplatin in Subjects with Platinum-Resistant Recurrent Ovarian Cancer
    Medical condition: Platinum-Resistant Recurrent Ovarian Cancer
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-005990-29 Sponsor Protocol Number: ENGOT-OV64/NSGO-CTU-SOLERO Start Date*: 2021-12-14
    Sponsor Name:Nordic Society of Gynaecological Oncology - Clinical Trial Unit (NSGO-CTU)
    Full Title: An Early Phase Randomized Trial of APX005M in BRCAwt Patients with Recurrent Ovarian Cancer
    Medical condition: Patients with histologically diagnosed epithelial ovarian, fallopian tube or primary peritoneal cancer with radiologically or histologically confirmation of relapsed disease, and with known BRCA wi...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016180 Fallopian tube cancer PT
    20.1 10022891 - Investigations 10080244 Peritoneal cancer index PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Prematurely Ended) DK (Prematurely Ended) NO (Prematurely Ended) FI (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-000837-23 Sponsor Protocol Number: UCL07/095 Start Date*: 2009-02-19
    Sponsor Name:University College London
    Full Title: mEOC: A GCIG Intergroup multicentre trial of open label carboplatin & paclitaxel +/- bevacizumab compared with oxaliplatin & capecitabine +/- bevacizumab as first line chemotherapy in patients with...
    Medical condition: Mucinous ovarian cancer, stages II-IV and stage I recurrent
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) FI (Prematurely Ended) IT (Completed) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-001276-38 Sponsor Protocol Number: ColoAd1-2001 Start Date*: 2015-10-15
    Sponsor Name:PsiOxus Therapeutics Ltd
    Full Title: A Clinical Study Of ColoAd1 Administered Intraperitoneally: Dose Finding and Proof of Concept in Platinum-Resistant Epithelial Ovarian Cancer
    Medical condition: Epithelial ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-005706-44 Sponsor Protocol Number: TOPO-LAPA/CFB/2007-05 Start Date*: 2008-01-11
    Sponsor Name:Centre François Baclesse
    Full Title: Etude de phase II évaluant l'association topotécan-lapatinib chez des patientes en rechute moins de 12 mois après une première ligne de chimiothérapie à base de platine pour un cancer de l'ovaire, ...
    Medical condition: Patientes atteintes d'un cancer de l'ovaire, ou de la trompe ou du péritoine en rechute moins de 12 mois après une première ligne de chimiothérapie à base de sels de platine.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10066697 Ovarian cancer recurrent LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-003871-32 Sponsor Protocol Number: AL3818-US-002 Start Date*: 2021-11-11
    Sponsor Name:ADVENCHEN LABORATORIES, LLC
    Full Title: A Phase 1/2a/3 Evaluation of the Safety and Efficacy of Adding AL3818 (Anlotinib, INN: Catequentinib), a Dual Receptor Tyrosine Kinase Inhibitor, to Standard Platinum-Based Chemotherapy in Subjects...
    Medical condition: Recurrent or metastatic endometrial, ovarian, fallopian tube, primary peritoneal, or cervical carcinoma.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014734 Endometrial cancer metastatic PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014736 Endometrial cancer recurrent PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057529 Ovarian cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-001836-44 Sponsor Protocol Number: UCL/11/0119 Start Date*: 2012-06-11
    Sponsor Name:University College London
    Full Title: A Phase II Trial to Assess the Activity of TroVax® (MVA-5T4) Versus Placebo in Patients with Relapsed Asymptomatic Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
    Medical condition: Patients with relapsed asymptomatic epithelial ovarian, fallopian tube or primary peritoneal cancer
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-002782-20 Sponsor Protocol Number: H3E-MC-JMHH Start Date*: 2005-04-15
    Sponsor Name:Eli Lilly and Company Limited
    Full Title: A Phase 1 and 2 Clinical Trial of ALIMTA (Pemetrexed) in Combination with Carboplatin in Patients with Recurrent Ovarian or Primary Peritoneal Cancer
    Medical condition: platinum sensitive recurrent ovarian or primary peritoneal cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2020-004264-26 Sponsor Protocol Number: VS-6766-201 Start Date*: 2021-07-09
    Sponsor Name:Verastem, Inc.
    Full Title: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (RAMP 201)
    Medical condition: Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Trial now transitioned) BE (Trial now transitioned) ES (Restarted) IT (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jun 21 07:48:01 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA